Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Yael L. Maxwell

December 13, 2023

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Daily News

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Yael L. Maxwell

October 12, 2023

News Daily News

TCTMD’s Michael O’Riordan Wins Digital Health Award

Shelley Wood

August 22, 2023

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

News Daily News

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Michael O'Riordan

May 03, 2023

News Daily News

Not All Diets Measure Up for Protecting the Heart: AHA

Caitlin E. Cox

April 28, 2023

News Daily News

AI Gleans Insights Into Statin Questions, Misinformation Online

L.A. McKeown

April 26, 2023

News Daily News

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Michael O'Riordan

February 16, 2023

Advertisement

Lp(a) Appears Tied to Myocardial Fibrosis: Observational Data

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

TCTMD’s Michael O’Riordan Wins Digital Health Award

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA

Not All Diets Measure Up for Protecting the Heart: AHA

AI Gleans Insights Into Statin Questions, Misinformation Online

Longer-Term ASCVD Risk Assessment Best for Younger Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content